You are here: Industry Insights > ProBioGen

News List

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development PharmaSources
May 30, 2024
ModeX will harness the power of ProBioGen's pioneering DirectedLuck® Transposase Technology, which enables the production of high-titer, stable expression cell lines that are critical to the success of ModeX's antibody program.
ProBioGen Was Granted a New Patent for DirectedLuck® Transposase Technology B3C newswire
January 17, 2024
ProBioGen announced today that the Japan Patent Office (JPO) issued the first patent for the company’s DirectedLuck® technology.
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients PharmaSources
May 05, 2023
April 12, 2023，ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002.
ProBioGen Delivers Strong 2022 Performance, Investing for Growth in 2023 PharmaSources
April 04, 2023
ProBioGen, the Berlin-based CDMO and technology provider, reported today that revenues for the fiscal year 2022 (FY22) grew 35% vs FY21.
Another Clinical Asset Using ProBioGen's GlymaxX® Technology Begins Phase III PharmaSources
January 26, 2023
ProBioGen today announced that a Novartis clinical candidate using its antibody-dependent cellular cytotoxicity (ADCC) technology, GlymaxX, has reached Phase III.
ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck® Transposase Technology PharmaSources.com
January 10, 2023
ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck® transposase technology.
Lutz Hilbrich Appointed as Senator to the Senate of Economy Europe b3cnewswire
March 07, 2022
MiGenTra and ProBioGen announce the appointment of Dr. Lutz Hilbrich, Chief Executive Officer of both companies, as Senator to the Senate of Economy Europe.
ProBioGen Signs a Commercial License Agreement with AstraZeneca Providing their GlymaxX® Technology b3cnewswire
February 11, 2022
ProBioGen announces a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology.
ProBioGen Announces Innovent as a New Partner Signing License of GlymaxX® Technology B3Cnewswire
January 14, 2022
ProBioGen today announced that Innovent Biologics, Inc. (1801.HK) has signed a multi-product license for ProBioGen's GlymaxX technology.
Imvaq Therapeutics Signs a Service and Commercial Product License to Use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform B3Cnewswire
January 07, 2022
ProBioGen AG is delighted to announce the execution of a service and commercial product license agreement with Imvaq Therapeutics, a biotech company developing innovative cancer immunotherapies.

Previous page 1 2 3 4 5 6 Next page